November 5-7, 2020

Virtual, Interactive Conference!

November 5, 2020 - 7:15 AM - 8:00 PM EST
November 6, 2020 - 7:15 AM - 5:50 PM EST
November 7, 2020 - 7:00 AM - 3:55 PM EST

An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology^®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators.

This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

• Review breast cancer biology, staging, and prognostic and/or predictive markers, in order to better individualize therapy and counsel patients regarding conventional and investigational treatment options
• Integrate biomarkers, molecular assays, and other risk assessment tools into treatment decision-making algorithms to optimize outcomes for patients with breast cancer
• Discuss current and evolving imaging options for diagnosing, staging, and monitoring breast cancer
• Incorporate current guidelines and evolving evidence on local treatment options, including new approaches in surgery and radiation therapy, into the management of patients with breast cancer
• Individualize selection of systemic therapies for patients with early-stage or advanced/metastatic breast cancer by taking into consideration efficacy and safety, as well as patient characteristics and tumor subtype
• Evaluate emerging clinical data and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
• Utilize supportive care strategies for preventing and managing treatment-related toxicities in patients receiving treatment for breast cancer
• Facilitate awareness of clinical trial opportunities based on knowledge of emerging agents and variances in care in the field of breast cancer management

• Learn from experts how to integrate biomarkers, molecular assays, and other risk assessment tools into treatment decision-making algorithms to optimize outcomes for patients with breast cancer

• Improve your knowledge about breast cancer biology, diagnosis, staging, and prognostic and/or predictive markers, in order to better select the most appropriate therapy for patients with breast cancer

• Learn how to incorporate current guidelines and evolving evidence on local treatment options, including new approaches in surgery and radiation therapy, into the management of patients with breast cancer

• Gain expert perspectives on individualizing the selection of systemic therapies for patients with early-stage or advanced/metastatic breast cancer by taking into consideration efficacy and safety, as well as patient characteristics and tumor subtype

• Acquire expert insights on how to use supportive care strategies to prevent and manage treatment-related toxicities in patients receiving treatment for breast cancer

This educational activity is supported by educational grants from AstraZeneca; Daiichi Sankyo Inc.; Eisai Inc.; Lilly; MacroGenics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation.; Pfizer Inc; Puma Biotechnology, Inc.; and Seagen Inc. (formally Seattle Genetics, Inc.)

For further information concerning Lilly grant funding, visit lillygrantoffice.com.

Physicians (CME)

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC designates this live activity for a maximum of 27.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (Contact Hours)

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 27.25 Contact Hours.

Maintenance of Certification (MOC) Points

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 27.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Surgical Oncologists/Surgeons

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit www.absurgery.org

An application will be submitted to the American Board of Radiology (ABR) for SAM review.

Qualified by the American Board of Radiology on October 6, 2020 in meeting the criteria for self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification Program. This activity has been qualified by the American Board of Radiology for 1.5 SAM credits.

Joyce O'Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX